In Segment C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment until eventually disease progression or even the participants are unable to tolerate the study drugs. General, our present-day work highlights the potential utilization of ARV-825 in combination https://howdoesabbv-744workincanc46801.idblogz.com/32559611/about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers